CN105263930B - 作为lrrk2抑制剂的芳基吡咯并吡啶衍生的化合物 - Google Patents

作为lrrk2抑制剂的芳基吡咯并吡啶衍生的化合物 Download PDF

Info

Publication number
CN105263930B
CN105263930B CN201480021665.9A CN201480021665A CN105263930B CN 105263930 B CN105263930 B CN 105263930B CN 201480021665 A CN201480021665 A CN 201480021665A CN 105263930 B CN105263930 B CN 105263930B
Authority
CN
China
Prior art keywords
pyridine
pyrrolo
amino
carbonitrile
formonitrile hcns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480021665.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105263930A (zh
Inventor
S·T·贝德福德
I-J·陈
王康
王一康
D·S·威廉姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vignali J (r & D) Ltd
H Lundbeck AS
Original Assignee
Vignali J (r & D) Ltd
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vignali J (r & D) Ltd, H Lundbeck AS filed Critical Vignali J (r & D) Ltd
Publication of CN105263930A publication Critical patent/CN105263930A/zh
Application granted granted Critical
Publication of CN105263930B publication Critical patent/CN105263930B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480021665.9A 2013-04-18 2014-04-14 作为lrrk2抑制剂的芳基吡咯并吡啶衍生的化合物 Active CN105263930B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201300231 2013-04-18
DKPA201300231 2013-04-18
PCT/EP2014/057482 WO2014170248A1 (en) 2013-04-18 2014-04-14 Arylpyrrolopyridine derived compounds as lrrk2 inhibitors

Publications (2)

Publication Number Publication Date
CN105263930A CN105263930A (zh) 2016-01-20
CN105263930B true CN105263930B (zh) 2017-06-09

Family

ID=59093654

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480021665.9A Active CN105263930B (zh) 2013-04-18 2014-04-14 作为lrrk2抑制剂的芳基吡咯并吡啶衍生的化合物

Country Status (8)

Country Link
US (3) US9499542B2 (enExample)
EP (1) EP2986608B1 (enExample)
JP (1) JP6461097B2 (enExample)
CN (1) CN105263930B (enExample)
AR (1) AR095885A1 (enExample)
ES (1) ES2642204T3 (enExample)
TW (1) TW201533043A (enExample)
WO (1) WO2014170248A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018537502A (ja) 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
PT3472153T (pt) * 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) * 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
WO2018155947A1 (ko) 2017-02-24 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
AU2018239798B2 (en) 2017-03-23 2020-08-27 Daegu Gyeongbuk Institute Of Science And Technology Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
SG11202005264PA (en) * 2017-12-05 2020-07-29 Oscotec Inc Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
RU2020118913A (ru) 2017-12-14 2022-01-14 Х. Лундбекк А/С (H. Lundbeck A/S) Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
WO2020023393A1 (en) * 2018-07-23 2020-01-30 Bioblocks, Inc. Kinase antagonists and methods for making and using them
KR101990739B1 (ko) * 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR101992059B1 (ko) * 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3168211A1 (en) 2019-01-18 2020-07-23 Voronoi Co., Ltd. Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease
KR102133595B1 (ko) * 2019-05-31 2020-07-13 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR20230091150A (ko) * 2020-10-29 2023-06-22 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
CN112852954A (zh) * 2021-03-16 2021-05-28 江苏贝格尔生物医药有限公司 一种检测lrrk2基因1628多态性的引物和探针及试剂盒
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
US20250361230A1 (en) * 2022-06-06 2025-11-27 The USA, as Represented by the Secretary, Dept. of Heath and Human Services LATS Inhibitors and Uses Thereof
CN119707961B (zh) * 2024-12-02 2025-10-24 重庆飞因科生物科技有限公司 吡啶并吡咯类氨基酸衍生物及其在制备富亮氨酸重复激酶2抑制剂中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090141A2 (en) * 2006-02-01 2007-08-09 Smithkline Beecham Corporation Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
TW200738709A (en) * 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
WO2008025947A1 (en) * 2006-08-31 2008-03-06 Vernalis (R & D) Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitors
CN101679347A (zh) * 2007-03-20 2010-03-24 柯瑞斯公司 作为hsp90抑制剂的稠和的氨基吡啶
WO2012138896A1 (en) * 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101565A2 (en) 2003-05-16 2004-11-25 Eisai Co., Ltd. Jnk inhibitors
EP1968568A4 (en) 2005-12-22 2011-04-13 Glaxosmithkline Llc HEMMER OF NUTS ACTIVITY
WO2008110508A1 (en) * 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity
KR101700229B1 (ko) * 2009-03-19 2017-01-26 메디칼 리서치 카운실 테크놀로지 화합물들
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738709A (en) * 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
WO2007090141A2 (en) * 2006-02-01 2007-08-09 Smithkline Beecham Corporation Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
WO2008025947A1 (en) * 2006-08-31 2008-03-06 Vernalis (R & D) Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitors
CN101679347A (zh) * 2007-03-20 2010-03-24 柯瑞斯公司 作为hsp90抑制剂的稠和的氨基吡啶
WO2012138896A1 (en) * 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
5-甲氧基-1H-吡咯并[3,2-b]吡啶-2-甲酸的合成;张立光等;《沈阳药科大学学报》;20100220;第27卷(第2期);第120-122页 *
Leucine-rich repeat kinase 2 inhibitors: a patent review (2006-2011);Xianming Deng等;《Expert Opinion on Therapeutic Patents》;20121106;第22卷(第12期);第1415-1426页 *

Also Published As

Publication number Publication date
EP2986608A1 (en) 2016-02-24
HK1222387A1 (en) 2017-06-30
JP6461097B2 (ja) 2019-01-30
JP2016516791A (ja) 2016-06-09
US9675594B2 (en) 2017-06-13
US20160102089A1 (en) 2016-04-14
TW201533043A (zh) 2015-09-01
US20140315901A1 (en) 2014-10-23
ES2642204T3 (es) 2017-11-15
AR095885A1 (es) 2015-11-18
EP2986608B1 (en) 2017-08-23
WO2014170248A1 (en) 2014-10-23
US9499542B2 (en) 2016-11-22
US20170020850A1 (en) 2017-01-26
CN105263930A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
CN105263930B (zh) 作为lrrk2抑制剂的芳基吡咯并吡啶衍生的化合物
US9920031B2 (en) Indole carboxamide compounds
EP3209651B1 (en) Carbazole derivatives
CN106232118A (zh) 杂芳族化合物及其作为多巴胺d1配体的用途
JP2022544700A (ja) 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子
WO2019000504A1 (zh) 5型磷酸二酯酶抑制剂及其制备方法和用途
KR20240012538A (ko) Map4k1 억제제로 사용하기 위한 피리미딘 화합물
CN110818683A (zh) 2-吡啶取代脲结构小分子化合物及其合成和应用
HK1222387B (en) Arylpyrrolopyridine derived compounds as lrrk2 inhibitors
KR20200017170A (ko) Ship2 저해활성을 보이는 신규한 피리딘 유도체 및 이를 유효성분으로 하는 약학 조성물
EA048523B1 (ru) Пиримидиновые соединения для применения в качестве ингибиторов map4k1
EA048250B1 (ru) Производные хинолина, как ингибиторы протеинкиназы
HK1220968B (en) Phosphatidylinositol 3-kinase inhibitors
HK1220968A1 (zh) 磷脂酰肌醇3-激酶抑制劑
HK1238642B (en) Carbazole derivatives
HK1238642A1 (en) Carbazole derivatives
OA18535A (en) Heteroramatic Compounds and their use as Dopamine D1 Ligands.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant